Skip to main content

Advanced Search

Projected result for your current search:: 0

Search Operators:

You can use operators in your search query to narrow down your results even more. Click on the search operator to see an explanation of how it works.
Finds documents with exactly this word group, in exactly this word order and spelling (e.g. "employer branding").
Finds documents with both search terms (e.g. sales AND bonus).
Finds documents with one or the other search term (e.g. porsche OR volkswagen).
Finds documents with all search terms. Blank space is understood as AND (e.g. man robot production).
Finds documents with no appearance of the word behind NOT (e.g. ford NOT "harrison ford").
Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g. COUNT(gear)>8).
Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
Finds documents with the search term in different spellings. "?" allows only one character (e.g. organi?ation).
Special characters are understood as AND (e.g. Miller Bros. & Sons).
 Log in
Top

Cancer Chemotherapy and Pharmacology

Issue 1/2025

Content (125 Articles)

Pharmacokinetic analysis of crushed venetoclax tablets combined with azacitizine for recurrent pediatric acute myeloid leukemia (AML)

Motohiro Matsui, Takeo Yasu, Atsushi Makimoto, Yuki Yuza

Influence of DPYD gene polymorphisms on 5-Fluorouracil toxicities in Thai colorectal cancer patients

Chalirmporn Atasilp, Natchaya Vanwong, Pavitchaya Yodwongjane, Phichai Chansriwong, Ekaphop Sirachainan, Thanyanan Reungwetwattana, Pimonpan Jinda, Somthawin Aiempradit, Suwannee Sirilerttrakul, Monpat Chamnanphon, Apichaya Puangpetch, Nipaporn Sankuntaw, Patompong Satapornpong, Thomas Fabienne, Chonlaphat Sukasem

Sulforaphane inhibits multiple myeloma cell-induced osteoclast differentiation and macrophage proliferation by elevating ferroportin1

Weichu Sun, Jingqi Sun, Wei Hu, Cong Luo, Zhongwei Lu, Fen He, Hongyan Zhao, Xi Zeng, Deliang Cao, Junjun Li, Chang Zhang, Jiliang Xia

Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)

Sarah E. Taylor, Sarah Behr, Kristine L. Cooper, Haider Mahdi, Denise Fabian, Holly Gallion, Frederick Ueland, John Vargo, Brian Orr, Eugenia Girda, Madeleine Courtney-Brooks, Alexander B. Olawaiye, Leslie M. Randall, Debra L. Richardson, Stephanie A. Sullivan, Marilyn Huang, Susan M. Christner, Sushil Beriwal, Yan Lin, Aman Chauhan, Edward Chu, Elise C. Kohn, Charles Kunos, S. Percy Ivy, Jan H. Beumer

Absorption, metabolism, and excretion of oral [14C] radiolabeled donafenib: an open-label, phase I, single-dose study in humans

Sheng Ma, Ling Yi, YiCong Bian, Binhua Lv, Cong Zhang, Chengwei Li, Hua Zhang, Liyan Miao

Intrathecal pemetrexed for leptomeningeal metastases in a patient with ALK-rearranged lung adenocarcinoma: a case report

Emelie Gezelius, Maria Planck, Bassam Hazem, Seema Nagpal, Heather Wakelee

Absorption, single-dose and steady-state metabolism, excretion, and pharmacokinetics of adagrasib, a KRASG12C inhibitor

Lisa Rahbaek, Cornelius Cilliers, Christopher J. Wegerski, Natalie Nguyen, Jennifer Otten, Lauren Hargis, Matthew A. Marx, James G. Christensen, Jonathan Q. Tran

Predictive factors for first dose reduction and interruption of lenvatinib after beginning of the standard dose in Japanese patients with thyroid cancer

Kazuma Fujita, Mitsuji Nagahama, Akifumi Suzuki, Chie Masaki, Kiminori Sugino, Koichi Ito, Masatomo Miura

Plasma clearance of 5-fluorouracil is more influenced by variations in glomerular filtration rate than by uracil concentration

  • Original Article

Alice Matheux, Laurine Collas, Maelle Grisard, Léa Goulaieff, François Ghiringhelli, Leïla Bengrine-Lefevre, Julie Vincent, Francoise Goirand, Bernard Royer, Antonin Schmitt

HER-2 SMASH

Celal Alandağ, Ayşegül Öztürk, Fatih Yulak, Zeynep Deniz Şahin İnan, Mustafa Özkaraca, Burak Batuhan Lacın, Ahmet Altun

Evaluation of urinary vanin-1 for the early prediction of cisplatin-induced acute kidney injury during neoadjuvant chemotherapy for esophageal cancer

Tomonobu Uchino, Yuna Iwano, Yasunori Miyazaki, Michiaki Nakajo, Misa Osawa, Erina Nagai, Yusuke Taki, Shinsuke Sato, Masaya Watanabe, Masakazu Takagi, Yoshiyuki Kagawa

Influence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemia

Safwat A. Mangoura, Mahmoud H. Abdel-Raheem, Hanan A. Eltyb, Mohammed S. Molla, Abeer M. R. Hussein

Pharmacokinetics of cisplatin in the systemic versus hyperthermic intrathoracic or intraperitoneal chemotherapy

Tao Zhang, Wei Mu, Cheng-gong Liao, Yan Hou, Jie Song, Wen Hu, Yun Wang, Dongxu Chen, Yu Chen, Linna Liu, Lili Liu

Variations in serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment

Miki Takenaka Sato, Takuya Araki, Hideaki Yashima, Yuya Ishikawa, Jun Morita, Yoshiko Maeda, Masayuki Ohbayashi, Noriko Kohyama, Yoshio Ogawa, Takashi Fukagai, Koujirou Yamamoto, Mari Kogo

Tenuigenin inhibits osteosarcoma growth via CIP2A/PP2A/NF-κB axis

Shuo Yang, Shasha Liu, Zixun Dai

DPYD genotype should be extended to rare variants: report on two cases of phenotype / genotype discrepancy

  • Case Report

Paul Vilquin, Yves Medard, Fabienne Thomas, Lauriane Goldwirt, Luis Teixeira, Samia Mourah, Evelyne Jacqz-Aigrain

Landscape analysis of adverse events and dose intensity for FDA approved oncology small molecules

  • Open Access
  • Brief Report

Keagan P. Collins, Donghua Yin, Yazdi K. Pithavala, Rajendar K. Mittapalli

Nanotechnology and nanobots unleashed: pioneering a new era in gynecological cancer management – a comprehensive review

Naina Kumar, Mishu Mangla

Pharmacokinetics, mass balance, and metabolism of [14C]PLB1004, a selective and irreversible EGFR-TKI in humans

Donghui Liu, Qian Li, Shu Yan, Xinyue Zhang, Weiqiang Li, Feiyu Wang, Lei Gao, Fei Geng, Haiyan Zhou, Panpan Ye, Furong Zhao, Weizhe Xue, Peilong Zhang, Xingxing Diao, Wei Zhao

Endoglin as a predictive biomarker for pemetrexed sensitivity in non-small-cell lung cancer: a cellular study

Ching-Yuan Cheng, Wen-Chen Chuang, Ching-Pin Lin, Che-Hsing Li, Hui-Yi Chang, Wen-Jun Wu, Ming-Fang Wu, Jiunn-Liang Ko

Targeting on the PI3K/mTOR: a potential treatment strategy for clear cell ovarian carcinoma

Kewei Zheng, Guanqin Jin, Rui Cao, Yi Gao, Jing Xu, Ranran Chai, Yu Kang

WT161, a selective HDAC6 inhibitor, decreases growth, enhances chemosensitivity, promotes apoptosis, and suppresses motility of melanoma cells

João Marcos Oliveira-Silva, Leilane Sales Oliveira, Carolina Berraut Chiminazo, Rafael Fonseca, Carlos Vinicius Expedito de Souza, Alexandre Ferro Aissa, Graziela Domingues de Almeida Lima, Marisa Ionta, Angel Mauricio Castro-Gamero

Population pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer

Aburough Abegesah, Do-Youn Oh, KyoungSoo Lim, Chunling Fan, Cecil Chen, Chong Kim, Julie Wang, Ioannis Xynos, Magdalena Zotkiewicz, Song Ren, Alex Phipps, Megan Gibbs, Diansong Zhou

A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome

Keri R. Maher, Danielle Shafer, Dale Schaar, Dipankar Bandyopadhyay, Xiaoyan Deng, John Wright, Richard Piekarz, Michelle A. Rudek, R. Donald Harvey, Steven Grant

Pharmacokinetic exposure and treatment outcomes of lenvatinib in patients with renal cell carcinoma and differentiated thyroid carcinoma

Marinda Meertens, Eline L. Giraud, Esbar Hassan, Sybrand W.J. Zielhuis, Tiemen T. Snels, Ingrid M. E. Desar, Janneke E. W. Walraven, Sofie Wilgenhof, Johannes V. van Thienen, Jan Paul de Boer, Neeltje Steeghs, Nielka P. van Erp, Alwin D. R. Huitema

Dihydropyrimidine enzyme activity and its effect on chemotherapy toxicity: importance of genetic testing

Alexia Shamaei Zadeh, Danielle Roberts, Abby Williams, Deepali Pandey, John L. Villano

Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)

Anuradha Krishnamurthy, Hong Wang, John C. Rhee, Diwakar Davar, Ryan H. Moy, Lee Ratner, Susan M. Christner, Julianne L. Holleran, Joshua Deppas, Carina Sclafani, John C. Schmitz, Steve Gore, Edward Chu, Christopher J. Bakkenist, Jan H. Beumer, Liza C. Villaruz

HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC

  • Open Access
  • NSCLC
  • Original Article

Kunihiko Funaishi, Kakuhiro Yamaguchi, Hiroki Tanahashi, Koji Kurose, Shinjiro Sakamoto, Yasushi Horimasu, Takeshi Masuda, Taku Nakashima, Hiroshi Iwamoto, Hironobu Hamada, Toru Oga, Mikio Oka, Noboru Hattori

Lipidomic profiling of plasma from patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1)

Masaki Ri, Shinsuke Iida, Kosuke Saito, Yoshiro Saito, Dai Maruyama, Arisa Asano, Suguru Fukuhara, Hideki Tsujimura, Kana Miyazaki, Shuichi Ota, Noriko Fukuhara, Eiju Negoro, Junya Kuroda, Shinichiro Yoshida, Eiichi Ohtsuka, Tsukamoto Norifumi, Takayuki Tabayashi, Nobuyuki Takayama, Toko Saito, Yasuhiro Suzuki, Yasuhiko Harada, Ishikazu Mizuno, Isao Yoshida, Masaki Maruta, Yasushi Takamatsu, Hiroo Katsuya, Makoto Yoshimitsu, Yosuke Minami, Keisuke Kanato, Wataru Munakata, Hirokazu Nagai

Retraction Note: Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma

Hui Zhang, Yan Guo, Yongsheng Song, Chao Shang

Food effect trial of the pharmacokinetics and safety of TQ05105 in healthy Chinese subjects

Jun Dai, Yang Cheng, Yannan Zhou, Yanli Wang, Zhengzhi Liu, Qing Ren, Zhengjie Su, Qiaohuan Deng, Haimiao Yang, Yingzi Cui

New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysis

Frank M. Balis, Elizabeth Rieger, Nancy J. Bunin, JoAnn Gardiner, Leslie M. Shaw, Timothy S. Olson, Michael C. Milone

Dose adjustment strategy for high-dose methotrexate-induced toxicities in pediatric acute lymphoblastic leukemia: based on population PK analysis and exposure-toxicity relationship

Ailing Cao, Yanping Guan, Jian Wang, Xinyu Li, Shu Liu, Qiaolan Xuan, Kunyin Qiu, Yating Zhang, Lvhong Xu, Jianpei Fang, Zhong Zuo, Min Huang, Xueding Wang, Dunhua Zhou

Thymine as potential biomarker to predict 5-FU systemic exposure in patients with gastro-intestinal cancer: a prospective pharmacokinetic study (FUUT-trial)

Maarten A. Hanrath, Evi Banken, Sebastian A. H. van den Wildenberg, Daan van de Kerkhof, Dirk Jan A. R. Moes, Michele Boisdron-Celle, Bianca J. C. van den Bosch, Ramon Bax, Pierre M. Bet, Jan Gerard Maring, Geert-Jan M. Creemers, Irene. E. G. van Hellemond, Maarten J. Deenen

Real-world pharmacokinetics of trametinib in pediatric low-grade glioma

Laurie Pagnot, Isaline Granger, Jérôme Guitton, Bertrand Favier, Antony Ceraulo, Cécile Faure-Conter, Pierre Leblond, Michael Philippe

Model-informed development of a cost-saving dosing regimen for enfortumab vedotin

Catharina JP Op ’t Hoog, Amy Rieborn, Dirk Jan AR Moes, Jeroen JMA Hendrikx, Michiel S. van der Heijden, Mira D. Franken, Tom van der Hulle, Michel van Kruchten, Annelieke ECAB Willemsen, Stijn LW Koolen, Emmy Boerrigter, Rob ter Heine

A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors

Susan C. Scott, Anna Farago, W. Victoria Lai, Marianna Zahurak, Michelle A. Rudek, Judy Murray, Michael A. Carducci, Tamar Uziel, Naoko Takebe, Steven D. Gore, Charles M. Rudin, Christine L. Hann

Evaluation of Bruton’s Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL)

Aziz Ouerdani, Belén Valenzuela, Nicoline Treijtel, Nahor Haddish-Berhane, Sanjay Desphande, Srimathi Srinivasan, Emma Smith, Juan José Perez Ruixo

Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia

Christelle Darstein, Deokyong Yoon, Yiqun Yang, Shruti Kapoor, Kohinoor Dasgupta, Shengyuan Wu, Yasunori Kawakita, Matthias Hoch, Kai Grosch, Sherwin K. B. Sy

Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature

Carolina Liguori, Simona Magi, Alessandra Mandolesi, Andrea Agostini, Gianluca Svegliati-Baroni, Andrea Benedetti Cacciaguerra, Alessandro Parisi, Elisa Tiberi, Marco Vivarelli, Andrea Giovagnoni, Gaia Goteri, Pasqualina Castaldo, Rossana Berardi, Riccardo Giampieri

RETRACTED ARTICLE: New recommendations for reversal of high-dose methotrexate cytotoxicity with folinic acid

Jesper Heldrup, Archie Bleyer, Laura Ramsey, Lauren Schaff, Brooke Bernhardt, Stefan Schwartz, Etienne Chatelut, Miriam Hwang, Carolina Ten, Martin Guscott, Scott Howard

Correction: HER-2 SMASH

Celal Alandağ, Ayşegül Öztürk, Fatih Yulak, Zeynep Deniz Şahin İnan, Mustafa Özkaraca, Burak Batuhan Lacın, Ahmet Altun

Acknowledgement to reviewers 2023

  • Acknowledgement

Acknowledgement to reviewers 2024

  • Acknowledgement

Alternative routes of drug administration: exposure of imatinib using different formulations

H. B. Fiebrich-Westra, O. Visser, A. B. Francken, E. J. Smolders

Population pharmacokinetic analysis of bevacizumab in Japanese cancer patients with proteinuria: a prospective cohort study

Takashi Masuda, Taro Funakoshi, Takahiro Horimatsu, Sho Masui, Daiki Hira, Marin Inoue, Kodai Yajima, Shunsaku Nakagawa, Yasuaki Ikemi, Junzo Hamanishi, Atsushi Takai, Shinya Yamamoto, Takeshi Matsubara, Masaki Mandai, Hiroshi Seno, Motoko Yanagita, Manabu Muto, Tomohiro Terada, Atsushi Yonezawa

Effect of repeated bolus and continuous doxorubicin administration on bone and soft tissue concentrations– a randomized study evaluated in a tumour-free porcine model

  • Open Access
  • Original Article

Andrea René Jørgensen, Mats Bue, Pelle Hanberg, Christina Harlev, Elisabeth Krogsgaard Petersen, Hans Christian Rasmussen, Jakob Hansen, Thomas Baad Hansen, Akmal Safwat, Maiken Stilling

An exposure–safety analysis to support the dosage of the novel AKT inhibitor capivasertib

Carlos Fernandez Teruel, Marie Cullberg, Ignacio González-García, Gaia Schiavon, Diansong Zhou

Influence of interleukin-6 on the pharmacokinetics and pharmacodynamics of osimertinib in patients with non-small cell lung cancer

Hayato Yokota, Kazuhiro Sato, Sho Sakamoto, Yuji Okuda, Masahide Takeda, Yumiko Akamine, Katsutoshi Nakayama, Masatomo Miura

The evaluation of the impact of NUDT15 variants on thiopurine metabolism in Japanese children with acute lymphoblastic leukemia

Yoichi Tanaka, Rintaro Ono, Miho Ashiarai, Ayako Sakurai, Atsushi Watanabe, Taichiro Tsuchimochi, Yosuke Hosoya, Ruri Hanajiri, Takeshi Inukai, Daisuke Hasegawa

Napabucasin targets resistant triple negative breast cancer through suppressing STAT3 and mitochondrial function

Limei Yuan, Yaqing Zhu, Gege Guan, Mei Liu

Evolution of computational techniques against various KRAS mutants in search for therapeutic drugs: a review article

  • Original Article

Ayesha Mehmood, Mohammed Ageeli Hakami, Hanan A. Ogaly, Vetriselvan Subramaniyan, Asaad Khalid, Abdul Wadood

Neurofilament light chain as a marker for neuronal damage: integrating in vitro studies and clinical findings in patients with oxaliplatin-induced neuropathy

Nina Lykkegaard Gehr, Christina Mortensen, Tore B. Stage, Malene Roland Vils Pedersen, Søren Rafael Rafaelsen, Jonna Skov Madsen, Dorte Aalund Olsen, Signe Timm, Lars Henrik Jensen, Torben Frøstrup Hansen, Nanna Brix Finnerup, Lise Ventzel

Pharmacokinetics, metabolism, and excretion of [14C]-valemetostat in healthy male participants, and in vitro plasma protein binding

Masaya Tachibana, Nicholas Siebers, Thuy Vu Craveiro, Miho Kazui, Tomoko Ikeda, Takako Shimizu, Shinichi Inaba, Malaz A. Abutarif

Potential role of endothelial dysfunction in hypertension and proteinuria in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab: a pilot prospective observational study

Satoru Nihei, Kazuki Saito, Tatsuki Ikeda, Takayoshi Oikawa, Koichi Asahi, Junichi Asaka, Kenzo Kudo

Pharmacokinetic profile of novel reduced-dose Danziten™ (nilotinib tablets) versus Tasigna® (nilotinib capsules): in vivo bioequivalence and population pharmacokinetic analysis

Michael Mauro, Jerald Radich, Paras Jain, David Sequeira, Francesco Bellanti, Dan Douer

Pharmacokinetics, mass balance, and metabolism of [14C]FCN-437c, a selective and potent CDK4/6 inhibitor in humans

Lei Gao, Sheng Ma, Shu Yan, Hua Zhang, Ling Tian, Lize Li, Lei Diao, Liyan Miao, Xiaoran Yang, Xingxing Diao

Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas

Geraldine O’Sullivan Coyne, Shivaani Kummar, Larry V. Rubinstein, Deborah Wilsker, Nancy Moore, Murielle Hogu, Richard Piekarz, Joe Covey, Jan H. Beumer, Katherine V. Ferry-Galow, Liza C. Villaruz, Melinda G. Hollingshead, Julianne L. Holleran, Joshua J. Deppas, Yves Pommier, Brian Ko, Barry C. Johnson, Ralph E. Parchhment, Percy Ivy, James H. Doroshow, Alice P. Chen

Effect of Metformin on vascular endothelial injury in patients with non-small cell lung cancer treated with chemotherapy combined with bevacizumab

Hongyan Li, Zhenye Pu, Jin Fang

From predictive biomarker to therapeutic target: the dual role of SLFN11 in chemotherapy sensitivity

Yue Feng, Yingze Li, Zhenhao Zhang, Yuxuan Dai, Xingchun Gou, Kejing Lao, Running Zhang

Novel desensitization protocol utilizing conventional formulations to mitigate Temozolomide-Related skin hypersensitivity

Morgan E. Cantley, Clyde Coleman, Rachael M. Morgan, Niharika Reddy, Sarah A. Sertich, John L. Villano

Clinical relevance of Nectin-4 downregulation and biological changes caused by cytotoxic chemotherapy in bladder cancer

Makito Miyake, Takuya Owari, Kota Iida, Sayuri Onishi, Nobutaka Nishimura, Tomomi Fujii, Cynthia N. Jinno, Hideki Furuya, Yuki Oda, Tatsuki Miyamoto, Mitsuru Tomizawa, Takuto Shimizu, Kenta Onishi, Shunta Hori, Yosuke Morizawa, Daisuke Goto, Yasushi Nakai, Nobumichi Tanaka, Noriyoshi Miura, Tadahiko Kikugawa, Takashi Saika, Charles Rosser, Kiyohide Fujimoto

Potential anticancer effects of sodium-glucose cotransporter protein 2 (SGLT2) inhibitors Canagliflozin and Dapagliflozin

Weiyu Dong, Yanyan Wang, Shaohua Fan

Targeting insulin-like growth factor-1 (IGF-1) by using metformin in non-diabetic metastatic breast cancer female patients: a randomized controlled trial

Hager Salah, Hoda Rabea, Mostafa S. Sheemy, Alshaimaa Ibrahim Rabie, Hebatallah Ahmed Mohamed Moustafa, Ahmed A. Elberry, Ahmed Hassan

Pharmacokinetics, safety, and tolerability of fedratinib in adults with moderate and severe hepatic impairment: results from the phase 1 FEDR-CP-001 trial

Yizhe Chen, Richard A. Preston, Thomas Marbury, William B. Smith, Massimo Attanasio, Mark Thomas, Michael Thomas, Bing He, Yongjun Xue, Atalanta Ghosh, Gopal Krishna, Ken Ogasawara

Pazopanib and antacids: insights from the WHO pharmacovigilance database

Kazuki Nishida, Yao Liang, Osamu Maeda, Angélique Da Silva, Yuichi Ando, Basile Chrétien

Peptides derived from the POU domain of BRN2 show antitumor activity against murine melanoma model cells in vitro and in vivo

Maria Carolina Mariano Cesar, Agnes Kobayashi Calvo de Sant’ana, Renato Arruda Mortara, Victória Santos Souza, Thaysa Paschoalin, Marco Antônio Soufen, Juliana Machado Anastácio, Erenildo F. Macedo, Fernanda Fernandes Miranda da Cunha, Dayane Batista Tada, Denise Costa Arruda

ETV1 genetic polymorphisms as a candidate prognosis biomarker of Gastrointestinal stromal tumor

Wei Zhuang, Minju Jo, Haibo Qiu, Wanlong Lin, Min Huang, Xueding Wang

Trends in renal function following vascular endothelial growth factor inhibitor administration in patients with cancer and diabetes mellitus

Yuma Shibutani, Miki Hayakawa, Mayu Ishizaka

Impact of altitude on hemoglobin dynamics and prognosis in patients with advanced hepatocellular carcinoma receiving antiangiogenic TKIs: A propensity score matched study

Mengyun Zhou, Xiang Zhao, Meng Zhang, Mao Peijing, Chilie Quncuo, Pubu Zhuoga, Bianba Qiongda, Meilang Chutso, Bian Ma Cuo, Bangchao Zhao, Guangfa Wang, Cheng Yuan

A case report: capillary leak syndrome in a patient receiving high-dose methotrexate, Tislelizumab and zanubrutinib for CNS lymphoma

Wenpeng Li, Yuxi Hou

Protective effect of celecoxib against capecitabine induced hand and foot syndrome in patients with colorectal Cancer

Ahmed M. Kettana, Tarek M. Mostafa, Amr A. Ghannam, Dalia R. El-Afify

Risk factors and prediction models for cardiotoxicity induced by anthracyclines in malignant chemotherapy

Pengxiang Zhang, Yan Zhang, Zheng Xue, Dongchao Liu, Dongliang Li, Bing Duan, Meina Zhao, Liang Yin, Hongjie Gao, Bulang Gao, Jie Mi

Evaluation of the pharmacokinetics of enasidenib in patients with hepatic impairment

Yiming Cheng, Jian Chen, Carlos Vigil, Shahram Khanzadeh, Anita Rampersad, Thomas Prebet, Yan Li

Unrecognized mutations in DPYD* 2 A wild-type rectal cancer patients receiving postoperative 5-FU-based chemotherapy - do they have a clinical impact?

P. Liersch, S. Dierks, R. Andag, T. Liersch, C. de Boer, J. Kreutzer, A. Hille, H. Sülberg, A. Leha, Julie Schanz

DNA-incorporated thioguanine to detect potential non-adherence to maintenance therapy in acute lymphoblastic leukemia

Mathilde Rønne Koch, Anna Sofie Buhl Rasmussen, Bodil Als-Nielsen, Ximo Duarte, Gabriele Escherich, Mats Heyman, Kristi Lepik, Johan Malmros, Jacob Nersting, Inga Johannsdottir, Riitta Niinimäki, Malene Johanne Petersen, Heidi Segers, Inge Margriet van der Sluis, Maria Thastrup, Goda Vaitkeviciene, Kjeld Schmiegelow, Linea Natalie Toksvang

Retraction Note: New recommendations for reversal of high-dose methotrexate cytotoxicity with folinic acid

Jesper Heldrup, Archie Bleyer, Laura Ramsey, Lauren Schaff, Brooke Bernhardt, Stefan Schwartz, Etienne Chatelut, Miriam Hwang, Carolina Ten, Martin Guscott, Scott Howard

Anti-tumor efficacy of RAF/MEK inhibitor VS6766 in KRAS-mutated colorectal cancer cells

Haixin Zhu, Gezi Yan, Junjie Ma, Bo Zhang, Youyou Yan, Lulin Zhu, Rong Dong, Nengming Lin, Biqin Tan

Model-informed drug repurposing of proton pump inhibitors for the prevention of oxaliplatin induced peripheral neuropathy: A real-world data analysis and pharmacometrics approach

Yasuhito Tsukushi, Kanade Koriyama, Shinji Kobuchi, Kenjiro Matsumoto, Yukako Ito, Toshiyuki Sakaeda

NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with “quadruple wild-type” (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated

Tanner J. Freeman, Thomas J. George, Samuel A. Jacobs, Greg Yothers, Tatjana Kolevska, Huichen Feng, Corey Lipchik, Sai Maley, Nan Song, Ashok Srinivasan, Melanie Finnigan, James L. Wade III, Gary L. Buchschacher Jr., Tareq Al baghdadi, Asheesh Shipstone, Daniel Lin, Shannon L. Puhalla, Carmen J. Allegra, Norman Wolmark, Katherine L. Pogue-Geile

A thymine-challenge test to prospectively evaluate dihydropyrimidine dehydrogenase activity for risk of severe 5-fluorouracil-induced gastrointestinal toxicity

Nuala Helsby, Katrina Sharples, Yu Jin Kim, David Porter, Kathryn Burns, Soo Hee Jeong, Sarah Benge, Sanjeev Deva, Ben Lawrence, Christopher Jackson, Richard North, R. Matthew Strother, John Duley, Michael Findlay

Biotransformation and disposition of C14-labeled sonrotoclax ([14C]BGB-11417) in preclinical safety species and characterization of unique contribution from gut microbiome

Tingting Cai, Dan Su, Zhiyu Tang, Jianmei Liu, Wei Tang, Yue Wu, Fan Wang

Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase

Sherwin K. B. Sy, Yiqun Yang, Christelle Darstein, Deok Yong Yoon, Kohinoor Dasgupta, Shruti Kapoor, Shengyuan Wu, Yasunori Kawakita, Matthias Hoch, Kai Grosch

A novel cardioprotective mechanism of rosuvastatin: restoring PINK1/parkin-mediated mitophagy via SIRT1/FOXO1 activation in doxorubicin-induced cardiotoxicity

Yomna S. Momen, Mohamed A. Kandeil, Mohamed O. Mahmoud

RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroids

Beverly A. Teicher, Thomas S. Dexheimer, Thomas Silvers, Nathan P. Coussens, Eric Jones, Steven D. Gore, Mark Kunkel, James H. Doroshow

Anlotinib in cancer therapy: mechanisms of action, clinical applications, and future perspectives

Jianhua Ding, Chai Hong Yeong, Lei Wang, Chunyan Shi, Long Li, Lijun Song, Wenxiu Ma, Peng Li

Clinical pharmacology and therapeutic applications of talazoparib: a comprehensive review

Saphal Lakshmi Pasupulati, Katiboina Srinivasa Rao, Sushil Sharma, C. Madhavrao, Gaurav Rangari, Arup Kumar Misra, L. V. Simhachalam Kutikuppala, T. Devika, Sandhya Rani Sarikonda

Effect of plasma exchange on tirabrutinib plasma concentration in a patient with lymphoplasmacytic lymphoma: A case report

Takuya Araki, Akiko Kaneta, Hisashi Takei, Nobuhiko Kobayashi, Hideaki Yashima, Junko Tsukamoto, Yuri Miyazawa, Yoshiyuki Ogawa, Hiroshi Handa, Koujirou Yamamoto

Population pharmacokinetic analysis of fluorouracil and oxaliplatin in the absence or presence of zolbetuximab in locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

Akihiro Yamada, Jianning Yang, Peter L. Bonate, Nakyo Heo, Srinivasu Poondru

Chronic treatment with carboplatin induces mechanical hypersensitivity and neurochemical changes in the mouse dorsal root ganglia and spinal cord

Arisai Martínez-Martínez, Lizeth Yazmin Ponce-Gomez, Juan Antonio Vazquez-Mora, Laura Yanneth Ramírez-Quintanilla, Héctor Fabián Torres-Rodríguez, Christopher M. Peters, Juan Miguel Jiménez-Andrade

Non-oncologic to oncologic drug: A systematic review of drug repurposing in cancer

Yarava Dhanush, Vakkalagadda Siva Ganesh

Tumor response and thyroglobulin change in differentiated thyroid carcinoma treated with dabrafenib plus trametinib

  • Original Article

Haruhiko Yamazaki, Nobuyasu Suganuma, Mei Kadoya, Katsuhiko Masudo, Soji Toda, Aya Saito

High MCM10 expression mediates TMZ resistance and promotes the progression of glioma

Qiusi Tian, Zhijun Bao, Yifei Zhao, Qun Zhang

Effects of infliximab, an anti-TNF-α, on cyclophosphamide-induced bone marrow toxicity

Koorosh Tabatabaei, Haleh Vaez, Amirhosein Ghafouri-Asbagh, Bahram Amouoghli Tabrizi, Mir Alireza Nourazar, Behrooz Shokouhi

Comment on: Dose adjustment strategy for high dose methotrexate-induced toxicities in pediatric acute lymphoblastic leukemia: based on population PK analysis and exposure toxicity relationship

Ian J. Cohen

Modulation of prostaglandin-endoperoxide synthase-2 (PTGS2) mediated VEGF-signalling pathway by oral metronomic chemotherapy in locally advanced oral squamous cell Carcinoma: A brief report

Mehta Vedant Kamal, Akhil Palod, Preetiparna Parida, Ananth Pai, Krishna Sharan, Vijetha Shenoy Belle, Rama Rao Damerla, Mahadev Rao, Naveena A. N. Kumar

Sacituzumab Govitecan initial dose reduction in polish patients with metastatic triple-negative breast cancer: impact on efficacy and safety

Małgorzata Pieniążek, Marcin Kubeczko, Manuela Las-Jankowska, Anna Polakiewicz-Gilowska, Aleksandra Łacko, Michał Jarząb, Zuzana Bielčiková, Renata Pacholczak-Madej, Miroslawa Püsküllüoğlu

Dosing chemotherapy in children with obesity: literature review and evaluation of local practices

Joshua Convert, Pierre Leblond, Perrine Marec-Berard, Anthony Ceraulo, Benoit Dumont, Michael Philippe

A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti–PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results

Jayesh Desai, Sanjeev Deva, Bo Gao, Kunyu Yang, Kenneth J. O’Byrne, Meili Sun, Tianshu Liu, Tarek Meniawy, Xinmin Yu, Mark Voskoboynik, Diwakar Davar, Marco Matos, Shiangjiin Leaw, Tahmina Rahman, Xiaofei Qu, Hugh Giovinazzo, Xin Chen, Yan Dong, Daphne Day

Pharmacokinetics of UGN‑102, an investigational mitomycin‑containing reverse thermal gel for the treatment of non-muscle invasive bladder cancer

Sandip M. Prasad, Michael J. Louie, Brent Burger, Victoria Tsurutis, Nikky Ugwuoke, Dalit Strauss-Ayali

Mirdametinib: FDA approved MEK inhibitor for neurofibromatosis type 1

Saara, Shweta Kamboj, Dimpy Rani

Larotrectinib-associated withdrawal symptoms resolved following initiation of GLP-1 receptor agonist: a case report

Reema Patel, John F. Deeken

Substitution of ifosfamide for cyclophosphamide in the TI-CE regimen: pharmacology and dose justification in a patient with refractory metastatic germ-cell tumor post-nephrectomy—A case report

Lotte M. G. Hulskotte, Loek A. W. de Jong, Alwin D. R. Huitema, Joost Sijm, Ingrid Desar, Minke Smits, Nielka P. van Erp

Thrombosis and cancer what do the recommandations say

Sihame Lkhoyaali, Oumaima Lamsyah, Roda Hassan Eltigani, Wydad Nadir, Saber Boutayeb, Hassan Errihani

Optimizing lazertinib therapy through GSTM1 genotyping: a strategy to reduce excess drug exposure and potential toxicity

  • Open Access
  • Original Article

Rob ter Heine, Bianca J. C. van den Bosch, Robin M. van Geel, Wouter H. van Geffen, Lizza E. L. Hendriks, Michel M. van den Heuvel, Simon E. Koele, Adrianus J. de Langen, Thijs H. Oude Munnink, Anthonie J. van der Wekken

Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences

Yangqingqing Zhou, Wunan Huang, Xinyue Hang, Yanlin He, Ruiyuan He, Chaosheng Gan

Simulation of perioperative Ibrutinib withdrawal using a population pharmacokinetic model and sparse clinical concentration data

Sakiko Kimura, Ken-ichi Sako, Nao Kikkawa, Yuta Nakamaru, Shunsuke Matsuo, Kana Kusaba, Mai Fujita, Keisuke Kidoguchi, Sho Okamoto, Yukie Yoda, Shinya Kimura, Chisato Shimanoe

Transient receptor melastatin channel in colorectal cancer: pathophysiological mechanisms and a promising drug target

Ala’a S. Shraim, Manal A. Abbas

Severe toxicity following genotype-guided reduced 5-FU dose in a heterozygous DPYD c.2846A>T carrier with stage III anal carcinoma: A case report

  • Case Report

Madeline L. Norris, David L. DeRemer, Julio D. Duarte, George P. Kim, Thomas J. George

Prediction of CYP3A4-mediated drug-drug interactions of a novel Bcl-2 inhibitor TQB3909 using physiologically based pharmacokinetic modeling

Hui Chen, Shixing Zhu, Anqi Yang, Xu Li, Xunqiang Wang, Wei Zhao, Xin Wang, Ding Yu

Assessing plastic waste associated with LC-MS/MS method validation procedures

Romain Beziat, Chan Laurent-Britel, Samuel Huguet, Manon Launay

Afatinib for a non-small cell lung cancer patient in hemodialysis: A case report and literature review

Yu Yan, Xin Zheng, Xue Zhao, Xiaoyan Si, Li Zhang

Association of IL12RB2, RORC, and class II HLA polymorphisms with severe erythema multiforme of regorafenib in Japanese patients with colorectal cancer

Geonwoo Lee, Remi Murase, Natsumi Matsumoto, Yutaro Kubota, Hiroo Ishida, Ken-ichi Fujita

A novel Ondansetron extended release injectable suspension (OERIS): evaluation of Safety, tolerability and pharmacokinetics in a phase I trial

Veerendra Kumar Panuganti, Chandrasekhar Varma Alluri, Venkata Ramalingayya Grandhi, Javeed Mohammad, Sanyasirao K. S. S. V. V., Mamatha Reddy Dundigalla, Pavan Kumar Madala

Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer

Stuthi Perimbeti, Anmbreen Jamroze, Dharmesh Gopalakrishnan, Rohit Jain, Changchuan Jiang, Julianne L. Holleran, Robert A. Parise, Robert Bies, David Quinn, Kristopher Attwood, Xiaozhuo Liu, Kelly Green, Jason S. Kirk, Jan H. Beumer, Dean G. Tang, Gurkamal Chatta

Selection of isatuximab dosing regimen in pediatric patients with leukemia using population pharmacokinetics

Claire Brillac, Dorothée Sémiond, Corina Oprea, André Baruchel, C. Michel Zwaan, Laurent Nguyen

Impact of adverse events on survival outcomes in patients treated with CDK4/6 inhibitors for advanced breast cancer

Martina Catalano, Gestiana Cekrezi, Irene De Gennaro Aquino, Delia Ravizza, Alexandra Paulet, Kristian Shtembari, Claudia De Angelis, Roberto Petrioli, Daniele Generali, Giandomenico Roviello

Mechanisms of resistance to antibody-drug conjugates in cancer: molecular barriers and pharmacological solutions

Lina Eltaib, Muhammad Afzal, Chandana Maji, H. Malathi, Kavita Goyal, Haider Ali, Gaurav Gupta, Md Sadique Hussain

6-gingerol alleviates chemotherapy-induced nausea and vomiting by inhibiting ferroptosis via the regulation of iron homeostasis

Wan Liang, Lei Feng, Siyu Han, Chenglu Yang, Binbin Ye, Ziyao Mo, Ke Nie

Association of DPYD rs4294451, plasma uracil concentration, and sex with 5-fluorouracil exposure in patients with gastrointestinal cancer

  • Open Access
  • Original Article

Gabriel A. Brooks, Dylan B. Ness, Kathryn C. Hourdequin, Gregory H. Ripple, Manik Amin, Sierra Lord-Halvorson, Wahab A. Khan, Sophie J. Deharvengt, Vincent Busque, Konstantin H. Dragnev, Wenyan Zhao, Tor D. Tosteson, Lionel D. Lewis

Potential clinical relevance of rare dihydropyrimidine dehydrogenase genetic variants identified using whole-exome NextGen sequencing in cancer patients with severe fluoropyrimidine toxicity

  • Original Article

Elizabeth Cui, Samantha Medwid, Ute I. Schwarz, Richard B. Kim

Presence of drug-drug interactions between esomeprazole and an ALK tyrosine kinase inhibitor (Dirozalkib)

Lin Fang, Xin Jiang, Kexiu Song, Ping Shi, Li Wang, Lingmei Xu, Xianghui Duan, Fei Liu, Feifei Sun, Rongxin Ban, Yaping Ma, Chenjing Wang, Yu Cao

Lack of effects of S-equol-containing supplement on the pharmacokinetics of oral hormone therapy drugs for breast cancer

Takehiko Sambe, Chiyo K. Imamura, Noriko Hida, Taigi Yamazaki, Takuya Mizukami, Kakei Ryu, Koya Fukunaga, Taisei Mushiroda, Haruna Miyakawa, Shigeto Uchiyama, Naoki Uchida, Shinichi Kobayashi

Benefit of plasma cystatin C for carboplatin individual dosing in a patient with spinal amyotrophy

Matthieu Gracia, Sabrina Marsili, Julien Vintejoux, Laurence Gladieff, Etienne Chatelut, Fabienne Thomas

Pharmacokinetic comparison of cisplatin administration via HIPEC and intravenous infusion in a porcine model

Christina Harlev, Elisabeth Krogsgaard Petersen, Mats Bue, Lone Kjeld Petersen, Johanne Gade Lilleøre, Anne Vibeke Schmedes, Bo Martin Bibby, Maiken Stilling

Dec 24
Issue: 6/2024
Dec 26
Issue: 1/2026

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Keynote webinar | Spotlight on progress in colorectal cancer

On-demand video coming soon

CRC remains a major global health burden, but advances in screening, treatment, and lifestyle-based prevention continue to reshape clinical practice. Gain insights into how the latest research can be leveraged to optimize patient care across the CRC continuum.

Prof. Antoni Castells
Prof. Harpreet Wasan
Prof. Edward Giovannucci
Notify me
Image Credits
Colon cancer illustration/© (M) KATERYNA KON / SCIENCE PHOTO LIBRARY / Getty Images